Yearly Archives: 2008

Quark siRNAs Examined Alone and in Combination with Chemotherapy
Fremont, CA October 13, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the […]

Data Validates Neuroprotective Effect of Quark’s New RNAi product on dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma
Fremont, CA September 25, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)- based therapeutics, today announced QPI-1007 as the Company’s first siRNA drug candidate based on its own […]

Clinical Program Leverages Quark’s RNAi Technology

Fremont, California, July 30, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME). PF-4523655 is a novel […]

Fremont, California, June 25, 2008 – Quark Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for its siRNA drug candidate, DGFi, in kidney transplantation. The Company expects its Phase I/II clinical study for prevention/treatment of Delayed Graft Function (DGF) in kidney transplant […]

Funds Will Support Clinical Development of Pipeline Products

Fremont, California, April 7, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, today announced the closing of a private financing totaling an aggregate of $27 million. The major investors are Investment vehicles of SBI Asset Management Co., Ltd. […]